Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– Important Translational Data for TIBSOVO® Underscore the High Clinical and Molecular Remissions Rate Observed in Combination with Azacitidine in IDH1 Mutant AML and Expand Understanding of...
-
– TIBSOVO® Net Revenue of $17.4 Million; 27% Growth from Q2 2019 – – Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission...
-
– Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating...
-
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
-
CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that...
-
– TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo – –...
-
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that...
-
– Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.4 g/dL – – Hemoglobin Responses Maintained in 19...
-
CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
-
Strong Topline Performance for IDH Inhibitors: TIBSOVO® Net Revenue Increased 50% from Q1 2019 to $13.7M; IDHIFA® Royalty Increased to $2.7M Achieved Important Expansion Opportunities for TIBSOVO®...